106
Participants
Start Date
February 28, 2014
Primary Completion Date
February 28, 2015
Study Completion Date
April 30, 2015
Anagrelide retard
Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
Thromboreductin
Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
AOP Orphan Investigational Site Bulgaria 2, Sofia
AOP Orphan Investigational Site Bulgaria 1, Pleven
AOP Orphan Investigational Site Russia 1, Moscow
AOP Orphan Investigational Site Russia 3, Yaroslavl
AOP Orphan Investigational Site Russia 2, Saint Petersburg
AOP Orphan Investigational Site Russia 5, Saint Petersburg
AOP Orphan Investigational Site Russia 4, Saint Petersburg
AOP Orphan Investigational Site Russia 6, Volgograd
AOP Orphan Investigational Site Austria 2, Linz
AOP Orphan Investigational Site Austria 1, Vienna
AOP Orphan Investigational Site Austria 3, Wels
AOP Orphan Investigational Site Lithuania 1, Kaunas
AOP Orphan Investigational Site Lithuania 2, Klaipėda
AOP Orphan Investigational Site Poland 5, Bialystok
AOP Orphan Insvestigational Site Poland 6, Gdansk
AOP Orphan Investigational Site Poland 4, Katowice
AOP Orphan Investigational Site Poland 3, Lublin
AOP Orphan Investigational Site Poland 2, Torun
AOP Orphan Investigational Site Poland 1, Warsaw
Lead Sponsor
AOP Orphan Pharmaceuticals AG
INDUSTRY